Pacific Biosciences of California Inc. buy UBS Group AG
Start price
17.11.23
/
50%
€7.17
Target price
17.11.24
€9.20
Performance (%)
-79.08%
End price
18.11.24
€1.50
Summary
This prediction ended on 18.11.24 with a price of €1.50. The BUY prediction by UBS_Group_AG for Pacific Biosciences of California Inc. performed very badly with a performance of -79.08%. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Pacific Biosciences of California Inc. | 17.087% | 17.087% | 6.836% |
| iShares Core DAX® | -1.586% | 5.028% | 6.332% |
| iShares Nasdaq 100 | -4.148% | -0.125% | 25.735% |
| iShares Nikkei 225® | -6.302% | 0.528% | 41.384% |
| iShares S&P 500 | -3.225% | 0.470% | 20.449% |
Comments by UBS_Group_AG for this prediction
In the thread Pacific Biosciences of California Inc. diskutieren
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $10.00 price target on the stock, down previously from $13.00.
Ratings data for PACB provided by MarketBeat
In the thread Trading Pacific Biosciences of California Inc.
Die von UBS_Group_AG gewählte maximale Laufzeit wurde überschritten
Stopped prediction by UBS_Group_AG for Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc.
Start price
Target price
Perf. (%)
€5.53
16.02.24
16.02.24
€11.13
16.02.25
16.02.25
-67.79%
17.02.25
17.02.25
